RSS Feeds
Search

Industry news

Raptor Pharmaceutical Provides Financial and Clinical Program Updates

In order to access this content you must be logged in and have a subscription to Pharmalicensing Intelligence.

Pharmalicensing Intelligence is a one-stop environment for time-conscious executives. Keeping you abreast of the latest developments in the life sciences industry, saving you time and money when you need it most.

Subscribe now for instant access to the benefits Pharmalicensing Intelligence has to offer. Find out more.

Company details

If you want to find out more about the company visit Raptor Pharmaceutical profile.

Related reports

Market Research Reports provided by reports.iptechex.com
Raptor Pharmaceuticals Corp. – Product Pipeline Review – Q1 2011
Jun 2011 - 52 pages - $500
Raptor Pharmaceuticals Corp. - Product Pipeline Review - Q4 2010
Nov 2010 - 62 pages - $500
Raptor Pharmaceuticals Corp. – Product Pipeline Review – H2 2011
Oct 2011 - 65 pages - $500
Raptor Pharmaceuticals Corp. (RPTP) - Strategic SWOT Analysis Review
May 2011 - 15 pages - $250
Raptor Pharmaceuticals Corp. (RPTP) - Financial and Strategic SWOT Analysis Review
Mar 2011 - 25 pages - $250
Raptor Pharmaceuticals Corp.-Therapeutic Competitors
Nov 2010 - 134 pages - $600
Raptor Pharmaceuticals Corp.-Detailed Product Pipeline
Nov 2010 - 64 pages - $750
Raptor Networks Technology, Inc. (RPTN) - Financial and Strategic SWOT Analysis Review
May 2011 - 25 pages - $250
Xerostomia Global Clinical Trials Review, Q1, 2011
Jan 2011 - 47 pages - $1,000
Sjogren’s Syndrome Global Clinical Trials Review, Q2, 2011
Jun 2011 - 55 pages - $1,000
More Related Market Research Reports >>>

Related news

Latest News

OXIS International, Inc. (OXIS) Announces the Launch of Oxis Consumer Products Subsidiary
From Oranienburg to the rest of the world: global market launch of Daxas
Straumann launches new CADCAM dental restoration system
Neuronetics selected by World Economic Forum as 2011 Technology Pioneer
QRxPharma to Sponsor Symposium at International Association for the Study of Pain Meetings
Bayer
PharmaNet Joins Medidata Solutions' CRO Partner Program
Randomized Controlled Trial Finds Masimo PVI Improves Fluid Management During Surgery
Rivaroxaban Successfully Demonstrated Non-Inferiority Compared to Standard of Care for the Prevention of Recurrent Venous Thromboembolism in Pivotal Phase 3 Study
Prometheus Launches the First Serogenetic Test to Predict Risk of Complications from Crohn's Disease
More news... | RSS Feed...

Most Viewed

OXIS International, Inc. (OXIS) Announces the Launch of Oxis Consumer Products Subsidiary

From Oranienburg to the rest of the world: global market launch of Daxas

Publication of Phase II trial results of NGR-hTNF in liver cancer by the British Journal of Cancer

Straumann launches new CADCAM dental restoration system

Rivaroxaban Successfully Demonstrated Non-Inferiority Compared to Standard of Care for the Prevention of Recurrent Venous Thromboembolism in Pivotal Phase 3 Study

Bayer

Neuronetics selected by World Economic Forum as 2011 Technology Pioneer

Pivotal Phase 3 Study Compares Tapentadol Extended Release Tablets to Placebo in Patients with Chronic Osteoarthritis Knee Pain

Advanced Life Sciences Sees Funding Opportunity for Restanza in New HHS Medical Countermeasure Report

Forest Laboratories, Inc. and Gedeon Richter Plc Announce Results from a Phase II Study of Cariprazine for the Treatment of Bipolar Depression

Therapeutic Target

Cardiovascular
Dermatology
Endocrine and Metabolic
Gastroenterology
Genitourinary
Hematology
Immunology and Allergy
Infection
Musculoskeletal
Neurology
Obstetrics and Gynecology
Oncology
Ophthalmology
Psychiatry
Pulmonary

Categories

Deals and Alliances
Development
Financial Results
Financings
Intellectual Property
Regulatory
Press releases
Deals review
Headlines
PR Newswire

Clients in focus...

Get the Flash Player to see this rotator.

© Copyright 1998-2013 IP Technology Exchange, Inc All rights reserved. Terms and Conditions | Contact us